| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
The Arab Drug Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م82.00 |
| 52 Week High | ج.م98.00 |
| 52 Week Low | ج.م56.00 |
| Beta | 0.60 |
| 11 Month Change | 1.99% |
| 3 Month Change | -12.94% |
| 1 Year Change | 22.66% |
| 33 Year Change | 25.00% |
| 5 Year Change | 181.30% |
| Change since IPO | 558.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADCI | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 2.4% |
| 1Y | 22.7% | 27.3% | 62.0% |
Return vs Industry: ADCI underperformed the EG Pharmaceuticals industry which returned 27.3% over the past year.
Return vs Market: ADCI underperformed the EG Market which returned 62% over the past year.
Price Volatility
| ADCI volatility | |
|---|---|
| ADCI Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in EG Market | 9.0% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: ADCI has not had significant price volatility in the past 3 months.
Volatility Over Time: ADCI's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | n/a | R. Samah Abdel-Yassiz | www.adcopharma-eg.com |
The Arab Drug Company engages in the manufacture and sale of pharmaceutical products. It offers anti-infectives, central nervous system drugs, dermatological drugs, and cardiovascular drugs, as well as animal health products in powders and solutions. The company exports its products to approximately 40 countries, including China, Korea, Turkey, Kazakhstan, Iraq, Syria, Jordan, Lebanon, Libya, Sudan, Somalia, Yemen, and Morocco.
The Arab Drug Company Fundamentals Summary
| ADCI fundamental statistics | |
|---|---|
| Market cap | ج.م492.00m |
| Earnings (TTM) | ج.م69.70m |
| Revenue (TTM) | ج.م729.67m |
7.1x
P/E Ratio0.7x
P/S RatioIs ADCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADCI income statement (TTM) | |
|---|---|
| Revenue | ج.م729.67m |
| Cost of Revenue | ج.م490.52m |
| Gross Profit | ج.م239.15m |
| Other Expenses | ج.م169.46m |
| Earnings | ج.م69.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.62 |
| Gross Margin | 32.78% |
| Net Profit Margin | 9.55% |
| Debt/Equity Ratio | 118.4% |
How did ADCI perform over the long term?
See historical performance and comparison